Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Suppression of type 1 diabetes in NOD mice by bifunctional peptide inhibitor: modulation of the immunological synapse formation.

Murray JS, Oney S, Page JE, Kratochvil-Stava A, Hu Y, Makagiansar IT, Brown JC, Kobayashi N, Siahaan TJ.

Chem Biol Drug Des. 2007 Sep;70(3):227-36.

PMID:
17718717
2.

Differential phosphorylation of NG2 proteoglycan by ERK and PKCalpha helps balance cell proliferation and migration.

Makagiansar IT, Williams S, Mustelin T, Stallcup WB.

J Cell Biol. 2007 Jul 2;178(1):155-65. Epub 2007 Jun 25.

3.

Mechanisms for human cytomegalovirus-induced cytoplasmic p53 sequestration in endothelial cells.

Utama B, Shen YH, Mitchell BM, Makagiansar IT, Gan Y, Muthuswamy R, Duraisamy S, Martin D, Wang X, Zhang MX, Wang J, Wang J, Vercellotti GM, Gu W, Wang XL.

J Cell Sci. 2006 Jun 15;119(Pt 12):2457-67. Epub 2006 May 23.

4.

Molecular basis of interaction between NG2 proteoglycan and galectin-3.

Wen Y, Makagiansar IT, Fukushi J, Liu FT, Fukuda MN, Stallcup WB.

J Cell Biochem. 2006 May 1;98(1):115-27.

PMID:
16365873
5.

Phosphorylation of NG2 proteoglycan by protein kinase C-alpha regulates polarized membrane distribution and cell motility.

Makagiansar IT, Williams S, Dahlin-Huppe K, Fukushi J, Mustelin T, Stallcup WB.

J Biol Chem. 2004 Dec 31;279(53):55262-70. Epub 2004 Oct 25.

6.

Design, structure and biological activity of beta-turn peptides of CD2 protein for inhibition of T-cell adhesion.

Jining L, Makagiansar I, Yusuf-Makagiansar H, Chow VT, Siahaan TJ, Jois SD.

Eur J Biochem. 2004 Jul;271(14):2873-86.

7.

NG2 proteoglycan promotes endothelial cell motility and angiogenesis via engagement of galectin-3 and alpha3beta1 integrin.

Fukushi J, Makagiansar IT, Stallcup WB.

Mol Biol Cell. 2004 Aug;15(8):3580-90. Epub 2004 Jun 4.

8.

Expression, purification, and structural study of the EC4 domain of E-cadherin.

Zheng K, Makagiansar IT, Wang M, Urbauer JL, Kuczera K, Siahaan TJ.

Protein Expr Purif. 2004 Jan;33(1):72-9.

PMID:
14680964
9.

Localized production of human E-cadherin-derived first repeat in Escherichia coli.

Makagiansar IT, Ikesue A, Nguyen PD, Urbauer JL, Urbauer RJ, Siahaan TJ.

Protein Expr Purif. 2002 Dec;26(3):449-54.

PMID:
12460769
10.

Increasing paracellular porosity by E-cadherin peptides: discovery of bulge and groove regions in the EC1-domain of E-cadherin.

Sinaga E, Jois SD, Avery M, Makagiansar IT, Tambunan US, Audus KL, Siahaan TJ.

Pharm Res. 2002 Aug;19(8):1170-9.

PMID:
12240943
11.

N-cadherin involvement in the heterotypic adherence of malignant T-cells to epithelia.

Makagiansar IT, Yusuf-Makagiansar H, Ikesue A, Calcagno AM, Murray JS, Siahaan TJ.

Mol Cell Biochem. 2002 Apr;233(1-2):1-8.

PMID:
12083363
12.

Disulfide bond formation promotes the cis- and trans-dimerization of the E-cadherin-derived first repeat.

Makagiansar IT, Nguyen PD, Ikesue A, Kuczera K, Dentler W, Urbauer JL, Galeva N, Alterman M, Siahaan TJ.

J Biol Chem. 2002 May 3;277(18):16002-10. Epub 2002 Feb 20.

13.

Synergistic inhibitory activity of alpha- and beta-LFA-1 peptides on LFA-1/ICAM-1 interaction.

Yusuf-Makagiansar H, Makagiansar IT, Hu Y, Siahaan TJ.

Peptides. 2001 Dec;22(12):1955-62.

PMID:
11786177
14.

Multidrug resistance-associated protein-1 functional activity in Calu-3 cells.

Hamilton KO, Topp E, Makagiansar I, Siahaan T, Yazdanian M, Audus KL.

J Pharmacol Exp Ther. 2001 Sep;298(3):1199-205.

PMID:
11504821
15.
16.

Supplemental Content

Loading ...
Support Center